DENTSPLY SIRONA (NASDAQ:XRAY) Share Price Passes Above 200-Day Moving Average – Time to Sell?

DENTSPLY SIRONA Inc. (NASDAQ:XRAY)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.64 and traded as high as $11.67. DENTSPLY SIRONA shares last traded at $11.65, with a volume of 4,795,828 shares traded.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on XRAY shares. Weiss Ratings cut DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. UBS Group cut their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Mizuho reduced their price objective on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Barclays dropped their target price on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Thursday, June 4th. Finally, Citigroup assumed coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, DENTSPLY SIRONA presently has an average rating of “Hold” and an average target price of $13.55.

DENTSPLY SIRONA Stock Up 5.0%

The company’s 50 day moving average price is $10.58 and its two-hundred day moving average price is $11.64. The firm has a market cap of $2.33 billion, a PE ratio of -3.70, a PEG ratio of 1.32 and a beta of 0.89. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The company had revenue of $880.00 million during the quarter, compared to analysts’ expectations of $841.80 million. During the same quarter last year, the company earned $0.43 earnings per share. The company’s revenue for the quarter was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts expect that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Brian P. Mckeon purchased 10,000 shares of DENTSPLY SIRONA stock in a transaction on Friday, June 12th. The stock was acquired at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the completion of the transaction, the director directly owned 10,000 shares in the company, valued at $101,200. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael J. Barber acquired 15,175 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the purchase, the director directly owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. This trade represents a 37.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 35,160 shares of company stock worth $351,179 over the last quarter. 0.46% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

Large investors have recently added to or reduced their stakes in the company. Southpoint Capital Advisors LP purchased a new stake in shares of DENTSPLY SIRONA in the first quarter worth $116,000,000. AQR Capital Management LLC lifted its stake in shares of DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares in the last quarter. Armistice Capital LLC boosted its holdings in DENTSPLY SIRONA by 1,044.0% in the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after buying an additional 5,234,587 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in DENTSPLY SIRONA by 662.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock worth $58,480,000 after buying an additional 4,003,606 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after buying an additional 2,172,343 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.